MENU
KMDA
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

KMDA stock forecast, quote, news & analysis

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company... Show more

Industry: #Biotechnology
KMDA
Daily Signal:
Gain/Loss:
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for KMDA with price predictions
Jul 24, 2026

KMDA in +3.26% Uptrend, growing for three consecutive days on July 21, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where KMDA advanced for three days, in of 249 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

KMDA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KMDA as a result. In of 103 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for KMDA turned negative on July 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 50-day moving average for KMDA moved below the 200-day moving average on July 16, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KMDA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for KMDA entered a downward trend on July 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.570) is normal, around the industry mean (46.269). P/E Ratio (20.171) is within average values for comparable stocks, (100.083). Projected Growth (PEG Ratio) (0.682) is also within normal values, averaging (1.733). Dividend Yield (0.035) settles around the average of (0.035) among similar stocks. P/S Ratio (2.257) is also within normal values, averaging (116.105).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. KMDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KMDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Dividends

KMDA paid dividends on April 07, 2026

Kamada Ltd KMDA Stock Dividends
А dividend of $0.25 per share was paid with a record date of April 07, 2026, and an ex-dividend date of March 23, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), BioCryst Pharmaceuticals (NASDAQ:BCRX), Bausch Health Companies (NYSE:BHC), Tilray Brands Inc. (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM), Aurora Cannabis (NASDAQ:ACB).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.01B. The market cap for tickers in the group ranges from 2.12K to 63.66B. AGN holds the highest valuation in this group at 63.66B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 12%. CPHI experienced the highest price growth at 38%, while SXTC experienced the biggest fall at -97%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was 195%. For the same stocks of the Industry, the average monthly volume growth was 93% and the average quarterly volume growth was 111%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 49
P/E Growth Rating: 65
Price Growth Rating: 60
SMR Rating: 87
Profit Risk Rating: 84
Seasonality Score: 12 (-100 ... +100)
View a ticker or compare two or three
KMDA
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company, which engages in pharmaceutical business

Industry PharmaceuticalsGeneric

Profile
Details
Industry
Biotechnology
Address
2 Holzman Street
Phone
+972 89406472
Employees
393
Web
https://www.kamada.com
KMDA in +3.26% Uptrend, growing for three consecutive days on July 21, 2026